NEW YORK--(BUSINESS WIRE)--Aug. 1, 2006--Bioenvision, Inc. (NASDAQ:BIVN) Bioenvision today announced its abstract on Suvus(TM) has been accepted for the British Association for the Study of the Liver’s 2006 Annual Meeting in Dublin. The meeting on September 7-8th at Trinity College provides Bioenvision the first opportunity to present data from a Phase II study of Suvus(TM) in chronic hepatitis C and refractory hepatitis C.
